CYP3A5 Genotype

Two people get a kidney the same week and go home on the same starting dose of tacrolimus. Tacrolimus helps keep the immune system from attacking a new organ. A week later one is sitting in the target blood range and the other is at roughly half of it, under-protected and feeling completely fine. One inherited letter of DNA can explain much of that gap.

That letter decides whether your body builds a working CYP3A5 enzyme. Its full name is cytochrome P450 3A5. This protein in the liver and gut takes tacrolimus apart. A small minority of people with European ancestry build it, roughly one in six. Most people with African ancestry do, and they need close to twice the dose to land in the same place.

Reading Your Result

Your report names two copies of the gene, one from each parent. A 1 copy works. A no-function copy such as 3, 6, or 7 changes the instructions so the finished protein does little or nothing.

• *Two working copies (1/1):* labs call this a normal or extensive metabolizer. You clear tacrolimus fastest and need the most drug to hold a level.
• *One working copy (1 plus a no-function copy):** an intermediate metabolizer. You still clear the drug quickly, and dosing advice treats you much like the group above.
• No working copies: a poor metabolizer. This is the usual result in people with European ancestry, about 85 percent of them, and about half of people with Asian ancestry. It is the minority result in people with African ancestry, closer to 30 percent. Standard tacrolimus dosing was built around this group.

The label is backwards from how it sounds. Poor metabolizer here doesn't mean something went wrong with you. It means you carry the version most drug labels were written around, and your standard dose is standard for a reason. The people who need a second look are the ones labeled normal and intermediate.

Transplant teams usually flatten the three groups into two. If you carry any *1 copy you're an expresser. If you don't, you're a non-expresser. Almost every dosing decision runs off that split.

Tacrolimus After a Transplant

If you carry a *1 copy, the usual weight-based starting dose will probably leave you under target. Expressers need roughly one and a half to two times the standard starting dose to reach the same blood level, and in some settings more than that. Pooled pharmacokinetic modeling puts the average clearance difference around 1.6-fold but finds that a dose increase of 75 percent or more is often what it actually takes, with clearance roughly doubled in people who have had a stem cell transplant.

That is also the published recommendation. CPIC, the group that writes gene-based prescribing guidelines, rates the recommendation as strong: start an expresser higher, keep the total under a per-weight ceiling, then adjust off blood levels the same way you would for anyone else.

The first weeks after a transplant are when rejection risk runs highest and when drug levels are least settled. Expressers spend more of that window below target, and they get there by a longer road of dose increases. Starting in the right neighborhood shortens the road.

The Dose Is Predictable, the Outcome Less So

Two randomized trials tested whether starting by genotype helps. A French trial in 280 kidney recipients found it did on the dosing side: 43 percent of the genotype-guided group were inside the target range at day 3 versus 29 percent of the standard group, and it took fewer dose changes to get them there. A Dutch trial in 240 living donor kidney recipients found no difference in how many people hit target at first steady state, about 36 percent either way, and no difference in rejection.

Both results can be true because they measure different things. The genotype predicts the dose you will end up on, which is why the first trial saw faster convergence. It doesn't predict your kidney's fate, because blood level monitoring finds and fixes a wrong starting dose within days anyway. That lack of a hard outcome benefit is the consistent finding, not a quirk of one trial: longer follow-up of the French cohort found no difference in biopsy-proven rejection or graft survival, and a pooled analysis of the randomized trials reached the same conclusion, better and faster target attainment without better clinical outcomes. What the result buys is a better first guess and a shorter stretch spent off target. It doesn't replace monitoring, and nobody claims it does.

Ancestry and Panel Coverage

Ancestry changes both your odds and how carefully you need to read the fine print. Most people with African ancestry are expressers. A small minority of people with European ancestry are, roughly 10 to 20 percent. East Asian and South Asian ancestry fall in between, with about half being expressers.

The 3 version isn't the only common no-function version. Two others, called 6 and 7, also shut the protein down, and both are found mainly in people with African ancestry, where they run at roughly 11 to 19 percent and 9 to 12 percent. They are vanishingly rare in European and Asian populations. A test that reads only the 3 spot can call someone an expresser who actually makes little or none of the enzyme. That person could be started on far more tacrolimus than they need.

This is exactly why the 2023 joint consensus from the pathology and pharmacogenetics societies says clinical panels should cover 3, 6, and *7. This panel uses sequencing, which can read more of the gene than a one-spot test. Still ask which CYP3A5 versions the report covers if you have African ancestry, because coverage varies between labs and panel generations.

Other Drugs in the CYP3A Family

CYP3A5 shares most of its work with CYP3A4, a far more abundant cousin that handles part of a large share of all prescription drugs. The two overlap on statins like atorvastatin and simvastatin, on midazolam, on cyclosporine, on several calcium channel blockers, and on many cancer kinase inhibitors.

For nearly all of those, CYP3A4 does enough of the job that your CYP3A5 result changes nothing about the dose. Tacrolimus is the exception, because CYP3A5 handles an unusually large share of it and because the gap between too little and too much is narrow.

The list of drugs the enzyme touches is long. The list where your result changes a prescription is one item long. Some studies have linked expresser status to less nerve damage from vincristine, a chemotherapy drug, but a meta-analysis of children treated with it found no significant association, and an animal model engineered to carry the human enzyme showed no effect on how vincristine moved through the body or on nerve damage. The findings aren't consistent enough to change how it's dosed.

When a Genetic Result Can Mislead

A genotype can't drift, but it can be read narrowly, read from donor DNA, or over-interpreted. Six situations account for most of the trouble.

• A narrow panel: a test that reads only the 3 position can miss 6 and *7 and mislabel someone with African ancestry as an expresser.
• A variant of uncertain significance: sequencing can find a rare change whose drug effect is unknown. That result should not set a dose by itself.
• A transplanted liver: much tacrolimus breakdown happens in the liver, so after a liver transplant the donor organ's genotype drives much of your clearance and your own result predicts less. CPIC applies its recommendation in liver recipients only when donor and recipient genotypes match.
• A donor stem cell or bone marrow transplant: blood and saliva can carry donor DNA. A pre-transplant sample, hair follicles, or another lab-approved recipient sample is safer.
• Tumor-only sequencing: a cancer test may read DNA from tumor cells rather than your inherited DNA. Use a germline pharmacogenetic result for dosing.
• Consumer DNA raw data: a direct-to-consumer service may list the same position in a downloadable file, but those files aren't built for prescribing and aren't confirmed by a clinical lab.

Your genotype is also only one input into a drug level. Age, a low red cell count, low albumin, diarrhea, and interacting drugs like azole antifungals, diltiazem, and grapefruit all push the number around, sometimes harder than the gene does. Azole antifungals alone cut tacrolimus clearance by close to 40 percent. An expresser taking a strong blocker of the same enzyme family may not need the higher dose at all.

A Test You Take Once

This result doesn't change. It's the same at 30 as it was at birth and will be the same at 80, so there's no trend to follow and no reason to repeat it unless the call itself is in doubt or the original panel read fewer versions of the gene than current ones do.

What does need tracking is everything downstream. If you're on tacrolimus, blood levels get checked often at first and then stretch out as they settle. Kidney function, magnesium, potassium, blood pressure, and blood sugar deserve a baseline before you start and ongoing checks after that, because this drug class wears on all of them.

If a transplant is a possibility rather than a certainty, getting the genotype ahead of time has more value than getting it later. The moment it matters is the moment nobody has time to wait on a send-out test.

Acting on an Expresser Result

An expresser result isn't something to sit on until a problem shows up. Hand it to the transplant pharmacist or nephrologist before the first dose is written, since the starting dose is the one decision this result actually changes.

• Ask what the panel read: if you have African ancestry, confirm the report covered 6 and 7 and not just *3. If the only source is consumer raw data, confirm it with a clinical test before using it for dosing.
• Get a kidney and electrolyte baseline: creatinine, cystatin C, a filtration rate, magnesium, and potassium before you start give you something real to compare against later.
• Flag your other drugs: azole antifungals, diltiazem, and some antibiotics block the same enzyme family and can cancel out the higher dose you would otherwise need.
• Tell your siblings and children: each child inherits one of your two copies, and a full sibling may carry the same pair you do.

If you're a non-expresser, the practical consequence is mostly reassurance: the standard dose is aimed at you. Keep the result in your record anyway, because the next person deciding a dose will want to know it was checked rather than assumed.